Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
BloodPublished 29 July 2010Open access
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler‐Stevenson, Steven A. Feldman
Citations1,335
SJR quartileQ1
SJR score5.82
SNIP3.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A patient with advanced follicular lymphoma was treated by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B- cell antigen CD19, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells.
Abstract
Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti-CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of B-lineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326.
Keywords
MedicineBiochemistry, Genetics and Molecular BiologyEngineering
Proceedings of the National Academy of SciencesSpecific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
1,606 Citations1993Zelig Eshhar, Tova Waks +2 more
BloodGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
1,406 Citations2009Laura A. Johnson, Richard A. Morgan +23 more
T cells expressing highly reactive TCRs mediate cancer regression in humans and target rare cognate-antigen-containing cells throughout the body, a finding with important implications for the gene therapy of cancer.
Proceedings of the National Academy of SciencesA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
1,245 Citations1997Yao‐Tseng Chen, Matthew J. Scanlan +8 more
R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Nature MedicineVirus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
1,190 Citations2008Martin Pulé, Barbara Savoldo +14 more
It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Molecular TherapyChimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
1,189 Citations2009Michael C. Milone, Jonathan D. Fish +12 more
It is suggested that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematologic malignancies and hence maximize their antitumor activity.
Proceedings of the National Academy of SciencesIdentification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
931 Citations1994Yutaka Kawakami, S Eliyahu +8 more
Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.
CellThe cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways
797 Citations1991Bryan Irving, Arthur Weiss
Data indicate that CD8/zeta can activate the appropriate signal transduction pathways in the absence of CD3 gamma, delta, and epsilon, and suggest that the role ofCD3 zeta is to couple the TCR to intracellular signal transduct mechanisms.
BloodAdoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
719 Citations2008Brian G. Till, Michael C. Jensen +14 more
The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
Nature MedicineEradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
662 Citations2003Renier J. Brentjens, Jean‐Baptiste Latouche +9 more
Biology of Blood and Marrow TransplantationAntitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
517 Citations2010Michael C. Jensen, Leslie Popplewell +5 more
These studies reveal the primary barrier to therapeutic efficacy is limited persistence, and provide the rationale to prospectively define T cell populations intrinsically programmed for survival after adoptive transfer and to modulate the immune status of recipients to prevent/delay antitransgene rejection responses.
The Journal of ImmunologyB4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
499 Citations1983Lee M. Nadler, K. C. Anderson +5 more
The observation that B4 is expressed on almost all early B cell tumors suggests that it may precede B1, CALLA, cytoplasmic mu, and B2 in early B Cell ontogeny.
Cancer ResearchCD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances<i>In vivo</i>Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
487 Citations2006Claudia Kowolik, Max S. Topp +8 more
In vivo, it is shown in vivo that adoptively transferred CD19RCD28(+) T cells show an improved persistence and antitumor effect compared with CD19R(+) T cells, implying that modifications to the CAR can result in improved therapeutic potential of CD19-specific T cells expressing this second-generation CAR.
Current Opinion in ImmunologyThe promise and potential pitfalls of chimeric antigen receptors
461 Citations2009Michel Sadelain, Renier J. Brentjens +1 more
If the immunogenicity of CARs can be averted, the versatility of their design and HLA-independent antigen recognition will make CARs tools of choice for T cell engineering for the development of targeted cancer immunotherapies.
Journal of ImmunotherapyConstruction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
402 Citations2009James N. Kochenderfer, Steven A. Feldman +6 more
In preparation for a clinical trial that will enroll patients with advanced B cell malignancies, a producer cell clone is generated that produces retroviruses encoding the anti-CD19 CAR, and sufficient retroviral supernatant is produced for the proposed clinical trial under good manufacturing practice conditions.
Molecular TherapyTreatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
381 Citations2010Renier J. Brentjens, Raymond Yeh +3 more
The chronology of Subject 4's treatment and the findings of an extensive postmortem analysis are described and reported on.
Cytometry Part B Clinical CytometryImmunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts
334 Citations2004Ellen G. van Lochem, Vincent H. J. van der Velden +4 more
A screening phase that precedes lineage‐specific classification phases should be sufficient to assess whether the BM has a normal or abnormal composition, as well as to identify the abnormal differentiation lineage.
Annual Review of ImmunologyDEVELOPMENT OF HUMAN LYMPHOID CELLS
327 Citations2005Bianca Blom, Hergen Spits
Lineage decisions are under control of transcription factors, and studies performed in the past decade have provided insight into transcriptional control of human lymphoid development, the results of which are summarized and discussed in this review.
BloodPhenotypic difference of normal plasma cells from mature myeloma cells
324 Citations1993H Harada, MM Kawano +8 more
Both CD19+CD56- and CD19-DC56+ plasma cells were found in all five cases of MGUS the authors tested, suggesting that MGUS consists of phenotypically normal plasma cells and myeloma cells.
BloodPhenotypic difference of normal plasma cells from mature myeloma cells
281 Citations1993H Harada, MM Kawano +8 more
PubMedIn vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
275 Citations1995Patrick Hwu, James C. Yang +5 more
It is shown that T cells can be gene modified to react in vivo against tumor antigens, defined by mAbs, which is potentially applicable to a number of neoplastic and infectious diseases and may allow adoptive immunotherapy against types of cancer not previously amenable to cellular immunotherapy.
LeukemiaFlow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL
235 Citations1999Paulo Lúcio, A Parreira +12 more
The immunophenotypic characterization and enumeration of different precursor and mature B cell subpopulations in normal bone marrow (BM) may form a frame of reference for the identification of aberrant phenotypes of precursor-B cell acute lymphoblastic leukemias (precursor-B-ALL) and may therefore be helpful in MRD detection.
BloodDetailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti- CD19 immunotoxins
226 Citations1988Fatih M. Uckun, W Jaszcz +8 more
The data presented confirm that CD19 is the most reliable B lineage surface marker and support the view that this B lineage-restricted surface determinant may be an important functional receptor.
Nature reviews. ImmunologySupernatural T cells: genetic modification of T cells for cancer therapy
149 Citations2005Michael H. Kershaw, Michele W.L. Teng +2 more
This Review describes how such T cells can circumvent many of the barriers that are inherent in the tumour microenvironment while optimizing T-cell specificity, activation, homing and antitumour function.
Cancer Immunology ImmunotherapyGene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
94 Citations2007C. B. H. W. Lamers, S.C.L. Langeveld +4 more
ScFv (G250)-receptor-mediated functions of the scFv(G250)+ T lymphocytes are, by and large, preserved in vivo upon administration, and may be reflected by fluctuations in plasma IFN-γ levels.
BloodCharacterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development
76 Citations1993S Pontvert-Delucq, J Breton-Gorius +5 more
Current Gene TherapyImmunotherapy of Human Cancers Using Gene Modified T Lymphocytes
24 Citations2009Juan F. Vera, Malcolm K. Brenner +1 more
How coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models is reviewed and how these approaches are being evaluated in human subjects is described.